Cohance Lifesciences Stock Plummets to New 52-Week Low at Rs. 688.05

Cohance Lifesciences has reached a new 52-week low, hitting Rs. 688.05 today, November 12, 2025. This marks a significant decline for the small-cap pharmaceutical and biotechnology company, which has seen its stock price drop by 43% over the past year, contrasting sharply with the Sensex's positive performance of 7.23% during the same period. Today's trading activity indicates that the stock is currently aligned with sector performance, following a nine-day streak of consecutive declines before gaining traction. However, it remains below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a challenging market position. Cohance Lifesciences has reported a notable increase in interest over the last six months, growing by 312.60% to Rs. 20.63 crore. However, its quarterly profit after tax has fallen by 41.1% compared to the previous four-quarter average, raising concerns about its financial stability. Additionally, the company has a high price-to-book value ratio of 15.6, indicating a premium valuation compared to its peers. With 100% of promoter shares pledged, the stock faces additional pressure in a declining market, contributing to its underperformance relative to broader market indices.